FDA Extends Compliance Date For GUDID For Some Devices After Discovering Security Flaw

August 25, 2015

In 2013, FDA introduced a new set of regulations that would establish a unique device identification system for medical devices. They also announced the dates for implementation, which would be done according to device classification. This set of regulations, called the Global Unique Device Identification Database (GUDID) would ensure compliance with the Agency’s required labeling and data submissions (full guidance here).

Earlier this month, FDA took the system offline after discovering a security vulnerability. Because of this, the Agency has announced that the compliance date for “non-class III implantable, life-supporting and life-sustaining medical devices” will be extended from September 24, 2015 to October 24, 2015 (see full guidance here).

We can help ensure your device and company is compliant with FDA regulations! Our unique approach, which combines a deep scientific knowledge with extensive regulatory expertise, has helped a number of our clients ensure compliance and get through FDA successfully. For more information on how we can help you, please contact us.

General Regulatory Regulatory Sciences

November 3, 2015

Draft Guidance for Microbial Vectors Used for Gene Therapy Outlines FDA Safety Concerns

Issues for Sponsors with INDs and CMC concerns FDA recently released a draft guidance entitled “Recommendations for Microbial Vectors Used for Gene Therapy” as a supplemental guidance to “Guidance...

Read the Full Article
Agency Alerts General Regulatory

September 17, 2015

FDA To Increase Tropical Disease Priority Review User Fee Rate In 2016

Starting October 1, 2015, the FDA tropical disease priority review user fee rate is set to increase to $2,727,000, up nearly $200,000 from 2015’s rate of $2,562,000. Under the Prescription Drug User...

Read the Full Article
Agency Alerts General Regulatory

November 19, 2015

FDA Holds Public Workshops to Discuss Regulatory Strategies for Next Generation Sequencing Diagnostics, Part 1

As we discussed in a previous FDA News article, the Agency is in the midst of developing “novel ways to optimize its regulation of Next Generation Sequencing (NGS) tests.” The Agency’s ultimate goal...

Read the Full Article